[{"address1": "4224 Campus Point Court", "address2": "Suite 210", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 202 6300", "website": "https://www.regulusrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.", "fullTimeEmployees": 29, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joseph P. Hagan M.B.A.", "age": 54, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 920728, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Crispina  Calsada CPA", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 500866, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher Ray Aker J.D.", "age": 62, "title": "Senior VP, General Counsel & Corporate Secretary", "yearBorn": 1961, "fiscalYear": 2022, "totalPay": 524790, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Preston S. Klassen M.D., M.H.S.", "age": 54, "title": "President, Head of Research & Development and Director", "yearBorn": 1969, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel J. Penksa", "age": 37, "title": "VP of Finance & Controller", "yearBorn": 1986, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Claire Susan Padgett M.S., M.T., Ph.D.", "title": "Senior Vice President of Clinical Operations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rekha  Garg M.D., M.S.", "title": "Senior Vice President of Clinical Development & Regulatory", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edmund  Lee Ph.D.", "title": "Vice President of Translational Medicine", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.36, "open": 2.45, "dayLow": 2.25, "dayHigh": 2.8, "regularMarketPreviousClose": 2.36, "regularMarketOpen": 2.45, "regularMarketDayLow": 2.25, "regularMarketDayHigh": 2.8, "beta": 1.444, "forwardPE": -2.4672897, "volume": 4957834, "regularMarketVolume": 4957834, "averageVolume": 2835361, "averageVolume10days": 16802790, "averageDailyVolume10Day": 16802790, "bid": 2.64, "ask": 2.65, "bidSize": 1300, "askSize": 1000, "marketCap": 53387932, "fiftyTwoWeekLow": 0.76, "fiftyTwoWeekHigh": 3.79, "fiftyDayAverage": 1.3922, "twoHundredDayAverage": 1.3901, "currency": "USD", "enterpriseValue": 21012506, "floatShares": 16319494, "sharesOutstanding": 20222700, "sharesShort": 54879, "sharesShortPriorMonth": 116302, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.0027, "heldPercentInsiders": 0.033350002, "heldPercentInstitutions": 0.59379, "shortRatio": 1.03, "shortPercentOfFloat": 0.0034999999, "impliedSharesOutstanding": 20821900, "bookValue": 1.397, "priceToBook": 1.889764, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -28771000, "trailingEps": -1.59, "forwardEps": -1.07, "pegRatio": -0.04, "lastSplitFactor": "1:10", "lastSplitDate": 1656460800, "enterpriseToEbitda": -0.711, "52WeekChange": 0.9504132, "SandP52WeekChange": 0.32974386, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RGLS", "underlyingSymbol": "RGLS", "shortName": "Regulus Therapeutics Inc.", "longName": "Regulus Therapeutics Inc.", "firstTradeDateEpochUtc": 1349789400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "cd43addf-be3b-3da4-8113-29f5cb221300", "messageBoardId": "finmb_36742485", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.64, "targetHighPrice": 12.0, "targetLowPrice": 2.0, "targetMeanPrice": 6.5, "targetMedianPrice": 6.0, "recommendationMean": 2.3, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 30782000, "totalCashPerShare": 1.522, "ebitda": -29557000, "totalDebt": 4064000, "quickRatio": 3.732, "currentRatio": 4.253, "debtToEquity": 14.381, "returnOnAssets": -0.41365, "returnOnEquity": -0.84709, "freeCashflow": -17511876, "operatingCashflow": -26896000, "financialCurrency": "USD", "trailingPegRatio": null}]